Communicating Across Cultures: A Big Tech and Big Pharma Challenge

To successfully navigate these differences, panelists emphasized the need for clear communication—especially early in the partnership. “Founders often assume everyone’s aligned just because they invested,” said Mas. “But if expectations haven’t been discussed, you end up with drama in the boardroom.”

When it comes to big tech and big pharma partnerships, misalignment is even more likely. “I’ve seen firsthand how tech and pharma bring very different assumptions to the table,” said Parramon. “Pharma thinks software guys can fix everything. Tech guys don’t think about evidence at all. If you haven’t aligned on the how—not just the goal—it will fall apart.”

Doctor emphasized that data is now a vital currency in medtech, especially with AI on the rise. “Many investors won’t look at you without a data strategy. However, healthcare is fragmented. Getting external data is a nightmare, so the data you collect from your own product becomes incredibly valuable.” He advised companies to treat data as a core asset, whether it’s related to symptoms, adherence, or outcomes.

For more information visit here: https://www.slideserve.com/James1267/communicating-across-cultures-a-big-tech-and-big-pharma-challenge

Comments

Post a Comment

Popular posts from this blog

Big Tech and Big Pharma: How Medtech Can Bridge the Gap

As technologies evolve and  healthcare innovation  accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with  big tech and big pharma  to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...
Read more